Elevance Health Announces Management Changes; CFO Mark Kaye to Expand Responsibilities to Include Carelon and Felicia Norwood to Lead Consolidated Health Benefits Organization
MWN-AI** Summary
Elevance Health, Inc. (NYSE: ELV) has announced key management changes aimed at streamlining decision-making and enhancing execution within its healthcare operations. Mark Kaye, the company’s CFO, will broaden his role to oversee Carelon, Elevance’s healthcare services division encompassing pharmacy services, behavioral health, value-based care, and care delivery. This strategic move recognizes Carelon’s vital contribution to the company’s mission of reducing healthcare costs, while its operational priorities will remain unchanged.
In conjunction with Kaye’s expanded responsibilities, Felicia Norwood, who currently serves as the Executive Vice President and Chief Health Benefits Officer, will now lead a consolidated Health Benefits organization. This realignment intends to bring together the company’s major Health Benefits sectors and core operations, fostering improved coordination and consistency across commercial and government health benefits.
Peter D. Haytaian, currently the Executive Vice President and President of Carelon, will exit his role effective May 4, 2026, to focus on family commitments. However, he will continue to support Elevance in a Special Advisor position through the end of 2026 to ensure a smooth leadership transition and continuity in client relationships.
Gail Boudreaux, President and CEO of Elevance Health, emphasized the importance of these changes in meeting evolving healthcare needs and enhancing operational clarity as the company prepares for scalable growth. Both Kaye and Norwood expressed their commitment to delivering sustainable growth and value while ensuring that the organization remains responsive to the needs of its customers and clients.
Elevance Health serves approximately 104 million consumers, aiming to improve the health of humanity through a broad suite of healthcare solutions, from medical and pharmacy services to behavioral and complex care. For further details, the company’s investor relations and media contacts are available for inquiries.
MWN-AI** Analysis
Elevance Health's recent management changes, notably the expansion of CFO Mark Kaye’s responsibilities to encompass Carelon and Felicia Norwood's leadership of the consolidated Health Benefits organization, signal a strategic shift aimed at enhancing operational efficiency and alignment across its healthcare services and health benefits sectors.
From an investment perspective, these changes could bode well for Elevance Health (NYSE: ELV) as they streamline decision-making processes and improve execution. Kaye’s leadership in overseeing Carelon’s operations, which include vital areas such as pharmacy and behavioral health services, aligns with the company's mission to lower healthcare costs and enhances its operational foundation. This move could enhance performance metrics, ultimately appealing to shareholders looking for sustainable growth and value creation.
By consolidating Health Benefits under Norwood, Elevance places itself in a position to improve coordination between its Commercial and Government sectors, which could lead to more consistent operational outcomes and a heightened ability to respond to marketplace demands. This streamlined approach should facilitate better product offerings and customer service, potentially driving customer satisfaction and retention.
Investors should also be mindful of potential risks associated with these leadership transitions, such as the uncertainty in operational continuity during the transition period and the market’s reaction to new leadership strategies. The forward-looking statements from the company caution about various risks, including industry regulations, economic conditions, and litigation factors that could impact financial performance.
In light of these factors, a cautiously optimistic approach may be prudent for investors. Monitoring Elevance’s performance post-transition, particularly regarding financial metrics related to Carelon’s service efficiencies and overall health benefits strategy, will be critical in assessing the long-term viability of this leadership restructuring. Overall, strategizing around market positioning and operational efficiency will likely yield valuable insights into Elevance Health’s future trajectory.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Elevance Health, Inc. (NYSE: ELV) today announced management changes designed to simplify decision-making and strengthen execution across Carelon and Health Benefits.
As part of these changes, Mark Kaye, Executive Vice President and Chief Financial Officer, will expand his responsibilities to include oversight of Carelon, the Company’s healthcare services operations including pharmacy services, behavioral health, value-based care, and care delivery capabilities. Carelon plays a critical role in advancing the Company’s strategy to lower the cost of care. Carelon’s operating priorities and client commitments remain unchanged.
Felicia Norwood, Executive Vice President and Chief Health Benefits Officer, will assume responsibility for the Company’s consolidated Health Benefits organization, bringing together the Company’s major Health Benefits businesses and core operating functions under a single accountable structure. This consolidation enhances coordination across Commercial and Government health benefits and supports a more consistent operating cadence across product, operations, and growth priorities.
Peter D. Haytaian has announced that he will transition from his role as Executive Vice President and President of Carelon effective May 4, 2026, in order to devote more time to family commitments. Haytaian will serve the Company as Special Advisor through December 31, 2026, to support an orderly leadership transition and ensure continuity across Carelon’s operations and client and partner relationships.
“Over the last several years, we have continued to evolve how we operate to meet the changing needs of healthcare and deliver for our customers, members, and clients,” said Gail Boudreaux, President and Chief Executive Officer of Elevance Health. “These management changes support disciplined execution and help us move with greater clarity and coordination as we continue to scale. I also want to thank Pete for his leadership and his commitment to supporting a smooth transition.”
“I look forward to leading the Carelon team as we build on our strong foundation, deliver for clients and partners, and execute with discipline that supports sustainable growth and long-term value,” said Kaye.
Norwood added, “Bringing Health Benefits together under a single accountable structure strengthens coordination and execution as we continue delivering for members and customers.”
About Elevance Health
Elevance Health is a lifetime, trusted health partner whose purpose is to improve the health of humanity. The company supports consumers, families, and communities across the entire healthcare journey – connecting them to the care, support, and resources they need to lead better lives. Elevance Health’s companies serve approximately 104 million consumers through a diverse portfolio of industry-leading medical, pharmacy, behavioral, clinical, home health, and complex care solutions. For more information, please visit www.elevancehealth.com or follow us @ElevanceHealth on X and Elevance Health on LinkedIn.
Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan,” “potential,” “predict” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems; failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity or sentiment related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260226217741/en/
Elevance Health Contacts:
Investor Relations:
Nathan Rich
Investor.Relations@elevancehealth.com
Media Contact:
Leslie Porras
Leslie.Porras@elevancehealth.com
FAQ**
How do the recent management changes at Elevance Health Inc Com ELV, particularly Mark Kaye's expanded role, impact the company's strategy for lowering healthcare costs and enhancing client services?
What specific measures will Felicia Norwood implement to improve coordination and execution across the consolidated Health Benefits organization at Elevance Health Inc Com ELV?
With Peter D. Haytaian transitioning to a Special Advisor role, what plans does Elevance Health Inc Com ELV have in place to ensure a smooth leadership transition and maintain continuity in Carelon’s operations?
How might the simplified decision-making structure announced by Elevance Health Inc Com ELV affect its overall performance in delivering healthcare services and improving member outcomes in the coming years?
**MWN-AI FAQ is based on asking OpenAI questions about Elevance Health Inc Com (NYSE: ELV).
NASDAQ: ELV
ELV Trading
1.62% G/L:
$291.77 Last:
829,361 Volume:
$291.32 Open:
